LENSAR LNSR 深 沪
已收盘 10-09 16:00:00 美东时间
6.37
-0.080
-1.24%
华盛通- 最 高6.5429
- 今 开6.43
- 成交量 1.53万股
- 最 低 6.37
- 昨 收 6.45
- 总市值 7826.10万
- 52周最高 12.94
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 4.95
- 委 比 78.10%
- 总股本 1228.59万
- 历史最高 17.31
- 量 比 0.36
- 振 幅 2.68%
- 历史最低 1.80
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
LUCID CAPITAL MARKETS Initiates Coverage On LENSAR with Buy Rating, Announces Price Target of $11
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on LENSAR (NASDAQ:LNSR) with a Buy rating and announces Price Target of $11.
09-28 20:09
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
美股牛股 | XChange飙升348%，拟收购智能体公司加速AI保险转型；ARX劲升43％
XChange飙升348%，拟收购智能体公司加速AI保险转型；ARX劲升43％，获私募溢价近5成收购；奥麦罗制药升逾26%，Q2业绩强劲，EPS扭亏为盈大超预期>>
08-14 16:05
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
LENSAR shares are trading higher after the company reported better-than-expected Q2 financial results.
LENSAR shares are trading higher after the company reported better-than-expected Q2 financial results.
08-14 02:30
BTIG Maintains Buy on LENSAR, Raises Price Target to $9
BTIG analyst Ryan Zimmerman maintains LENSAR (NASDAQ:LNSR) with a Buy and raises the price target from $7 to $9.
08-14 00:05
LENSAR Q2 2026 Earnings Call: Complete Transcript
LENSAR (NASDAQ:LNSR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access...
08-13 21:22
LENSAR Q2 EPS $0.10 Beats $(0.17) Estimate, Sales $16.495M Beat $14.650M Estimate
LENSAR (NASDAQ:LNSR) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.17) by 162.5 percent. This is a 166.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $16.495 million which ...
08-13 19:02
LENSAR Shareholders Approve Directors and Executive Pay
LENSAR ( ($LNSR) ) has provided an announcement. On August 4, 2026, LENSAR held...
08-11 06:18
